Diffuse large B-cell lymphoma (DLBCL) is an aggressive form of blood cancer and the most common form of non-Hodgkin lymphoma, accounting for one out of every three cases of NHL diagnosed in the United States.
Previously, an estimated 73% of DLBCL patients will relapse or not respond to treatment, however a new treatment option is giving hope to DLBCL patients.
Breyanzi is a new T cell therapy has been approved by the FDA to treat certain blood cancers.
Learn more about treatment options for lymphoma here.
